• Horizon Space Acquisition I Corp. entered a definitive business combination agreement with clinical-stage biopharma ArcheNova Biotech.
• The deal would create a new Cayman Islands parent, ArcheNova Technology, expected to list on Nasdaq upon closing.
• Transactions include mergers that leave HSPO and ArcheNova as wholly owned subsidiaries of the new parent.
• Consideration will be paid in parent ordinary shares to HSPO and ArcheNova shareholders; HSPO warrants will convert into parent warrants.
• Closing is targeted for the first quarter of 2027, subject to shareholder and regulatory approvals and other customary conditions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Horizon Space Acquisition I Corp. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202610130700ACCESSWRNAPR_____1235647) on October 13, 2026, and is solely responsible for the information contained therein.